MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Acquisitions Propel Growth

NodeGuardian · 2026-03-07T15:32:52+00:00

MannKind Corp reported record Q4 2025 revenue of $112 million, a 46% year-over-year increase, and acquired SC Pharmaceuticals. Expected 2026 revenue exceeds $450 million, driven by product launches and strategic investments, but faces challenges from market competition and financial strains.

NodeGuardian

2026-03-07 15:32:52

Abstract generation in progress

MannKind Corp (MNKD) reported record Q4 2025 revenue of $112 million, a 46% increase year-over-year, and completed the acquisition of SC Pharmaceuticals. Despite a GAAP net loss, the company anticipates over $450 million in revenue for 2026, driven by strategic investments, product launches like the Afrezza pediatric approval and Furoix auto-injector, and the advancement of its MNKD 201 idiopathic pulmonary fibrosis program with blockbuster potential. Challenges include potential variability in Tyvaso DPI sales, competitive pressures in the PAH market, and the financial strain of heavy investment in pipeline and infrastructure.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes